Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: bob s who wrote (1053)	6/13/1999 6:10:00 PM
From: Mike McFarland	Respond to of 3202

I got a 16 page mailer from this fellow--A one year subscription to technology investing for $200. I think I will pass, but I did take the time to read the mailer. His "Technology Investing" junk mail advert has the feel of a late night infomercial, but then again, they all are like that--Louis Ruyekser's junk mail is just as bad. His mailer has some fairly transparent allusions to Geron--although he doesn't state the name of the company, a nine year old kid could do a quick search on telomere and reveal that pick (maybe he is selling). There is an insert about patents with the mailer, it has a list "here is a partial list of the diseases and ailments for which there now exist patented remedies" (I just love the choice of words, remedies-- hey Mike Murphy, if you lurk here on SI, lose the snake oil approach, and include a list of gene therapy companies--and a free thousand page primer on the challenges these companies face--that's something you could sell, well, at least to me, heheh, but I suppose snake oil is what the masses want, gotta understand your audience). Anyway, he has Glaxo listed for an Alzheimer's gene, Myriad for a brain cancer gene, Progenitor for epilepsy, MLNM/Hoffmann La Roche for an Obesity Gene, HGSI for arthritis, MLNM for melanoma, MYGN/Novartis for a breast and ovarian cancer gene, Axys for a blindess gene. Geeze, how can a person carry on in this superficial way about the promise of genes and how patenting them will make companies rich--and then turn around and sell Incyte? What do you suppose the "clouds" are--Celera, SNP consortium, or the fact that Incyte is in a trading range from $18 to $25 and we all could have traded it several times. Maybe that is what Murphy is doing. Well, cant knock a guy for churning and trading, since I cut by 80% the number of trades I make, I've not made any money. So let's all churn Incyte--wasn't it the consensus of the thread that Incyte is the clear leader in the are of genomics data, and had a terrific business model? Churn churn churn. Just leaves a bad taste in my mouth. Nobody ever got rich churning Microsoft, all you had to do was buy and wait a decade.

To: bob s who wrote (1053)	6/13/1999 10:21:00 PM
From: George Sepetjian	Respond to of 3202

Michael Murphy-JOKE Pay attention to this newsletter writer at your own risk. His record speaks for itself-Loser. Looking for reliable info on the biotech industry. Go to signalsmag.com

To: bob s who wrote (1053)	6/14/1999 2:43:00 PM
From: LLCF	Read Replies (1) \| Respond to of 3202

<Michael Murphy is recommending selling INCY due to the clouds over the next year or so. > He was pounding the table [buy] when it dipped below his "buy level" a while back [think it was mid-20's]. His negative points are: - doesn't see big pharma paying higher prices for the service [revenue growth] - temporarily saturated their customer base with no substantial sales increment in sight. - doesn't see Big Pharma paying up for their expanding amount of data. - Wall street hasn't forgiven INCY for last years decision to invest in the future. - unhappy with the departure of CFO Dinise Gilbert. Says he may be more positive in a few months when it's trading in the low teens. DAK